Edition:
India

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

4.50USD
7 Dec 2018
Change (% chg)

-- (--)
Prev Close
$4.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,034
52-wk High
$8.74
52-wk Low
$4.20

Latest Key Developments (Source: Significant Developments)

Mesoblast Ltd Says Qtrly Loss Attributable $19.5 Mln
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Mesoblast Ltd ::QTRLY LOSS ATTRIBUTABLE $19.5 MILLION VERSUS LOSS OF $7.0 MILLION.QTRLY REVENUE $11.6 MILLION VERSUS $1.2 MILLION."ANTICIPATE THAT WE MAY CONTINUE TO INCUR SIGNIFICANT LOSSES FOR FORESEEABLE FUTURE".ANTICIPATE THAT COMBINED WORLDWIDE TURNOVER OF MESOBLAST GROUP WILL BE IN EXCESS OF A$20.0 MILLION FOR FY ENDED JUNE 2019.  Full Article

Mesoblast Expands Partnership With JCR Pharmaceuticals
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Mesoblast Ltd ::EXPANDS PARTNERSHIP WITH JCR PHARMACEUTICALS FOR TREATMENT OF WOUND HEALING IN EPIDERMOLYSIS BULLOSA.  Full Article

Mesoblast Says FY Loss Attributable To Owners Of Mesoblast $35.3 Mln
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Mesoblast Ltd ::FY LOSS ATTRIBUTABLE TO THE OWNERS OF MESOBLAST LIMITED $35.3 MILLION VERSUS LOSS $76.8 MILLION.FY TOTAL REVENUE $17.3 MILLION VERSUS $2.4 MILLION.SUBJECT TO ACHIEVING CERTAIN MILESTONES,ADDITIONAL $50 MILLION MAY BE AVAILABLE UNDER EXISTING ARRANGEMENTS WITH HERCULES CAPITAL & NOVAQUEST.  Full Article

Mesoblast Ltd Enters Alliance With Tasly Pharmaceutical Group
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Mesoblast Ltd ::ENTERED INTO A STRATEGIC ALLIANCE WITH TASLY PHARMACEUTICAL GROUP.DEAL FOR DEVELOPMENT IN CHINA OF CO'S PRODUCT FOR TREATMENT OR PREVENTION OF CHRONIC HEART FAILURE AND ACUTE MYOCARDIAL INFARCTION.UNDER ALLIANCE, MESOBLAST WILL RECEIVE US$40 MILLION ON CLOSING.  Full Article

Mesoblast Ltd Says Enters US$50 Mln Financing With Novaquest Capital
Monday, 2 Jul 2018 

July 2 (Reuters) - Mesoblast Ltd ::ENTERS US$50 MILLION FINANCING WITH NOVAQUEST CAPITAL FOR REMESTEMCEL-L IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE.NOVAQUEST WILL PROVIDE A NON-DILUTIVE US$40 MILLION, EIGHT-YEAR TERM LOAN AND PURCHASE US$10 MILLION OF MESOBLAST COMMON SHARES.  Full Article

Mesoblast Appoints Josh Muntner As Its New CFO
Thursday, 31 May 2018 

May 31 (Reuters) - Mesoblast Ltd ::APPOINTS JOSH MUNTNER AS ITS NEW CHIEF FINANCIAL OFFICER.MUNTNER TO REPLACE PAUL HODGKINSON.  Full Article

Mesoblast Posts Qtrly Loss Attributable $21.1 Million
Thursday, 31 May 2018 

May 31 (Reuters) - Mesoblast Ltd ::QTRLY REVENUE $1.1 MILLION VERSUS $901,000 .QTRLY LOSS ATTRIBUTABLE $21.1 MILLION VERSUS LOSS $9.8 MILLION."THERE IS UNCERTAINTY RELATED TO GROUP'S ABILITY TO PARTNER PROGRAMS, RAISE CAPITAL OR DEBT AT TERMS TO MEET GROUP'S REQUIREMENTS".THERE IS UNCERTAINTY RELATED TO CO'S ABILITY TO SUSTAINABLY MAINTAIN IMPLEMENTED COST REDUCTIONS AND FURTHER DEFER PROGRAMS ON TIMELY BASIS.  Full Article

Mesoblast To Develop Cell-Based Immunotherapies For Solid Cancers With Cartherics
Tuesday, 29 May 2018 

May 29 (Reuters) - Mesoblast Ltd ::PARTNERS WITH CARTHERICS TO DEVELOP 'OFF-THE-SHELF' CELL-BASED IMMUNOTHERAPIES FOR SOLID CANCERS.PROGRAM WILL BE FUNDED BY A$12.6 MILLION FROM COLLABORATORS IN AUSTRALIAN GOVERNMENT'S COOPERATIVE RESEARCH CENTRES PROGRAM.  Full Article

Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Mesoblast Ltd ::‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​.  Full Article

Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mesoblast Ltd ::MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT.MESOBLAST LTD - TOP-LINE RESULTS FROM PHASE 3 TRIAL ARE EXPECTED IN Q1 2018.  Full Article